Z. John Zhong

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Sandra Navarra, Renato Guzmán, A Gallacher et al. · The Lancet · 2011 · 2K citations

Medicine, Immunology, Pharmacology +11

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Richard Furie, Michelle Petri, Omid Zamani et al. · Arthritis & Rheumatism · 2011 · 1.7K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study of belimumab in patients with active systemic lupus erythematosus

Daniel J. Wallace, William Stohl, Richard Furie et al. · Arthritis Care & Research · 2009 · 595 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Novel evidence‐based systemic lupus erythematosus responder index

Richard Furie, Michelle Petri, Daniel J. Wallace et al. · Arthritis Care & Research · 2009 · 485 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +17

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus

William Stohl, Falk Hiepe, Kevin Latinis et al. · Arthritis & Rheumatism · 2012 · 416 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +17